Work

Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer

Year: 2026

Type: article

Abstract: Background: Comparative real-world evidence for camrelizumab plus famitinib versus PD-1 inhibitor plus platinum- and/or taxane-based chemotherapy with or without bevacizumab in persistent, recurrent, or metastatic cervical ca... | Find, read and cite all the research you need on Tech Science Press

Source: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics

DOI: 10.32604/or.2026.088774

Authors: Xiaojing Liu, Beibei Hua, Yang Xia, Huijie Huang, Areai Hakewati, Zeze Jin, Tumaris Halifu, Zaihua Xu

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W7223674945

FWCI:

Cites:

Cited by:

Related to: 10